Search This Blog

Thursday, December 30, 2021

Ocugen Partner Bharat: Positive Data From COVAXIN in Children 2 – 18

 

  • COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+

  • Adverse events were primarily mild, and no serious adverse events (SAEs) were noted

  • Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up

  • No cases of myocarditis or blood clots were reported, as expected with inactivated vaccines

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.